Medicine and Health Sciences Commons^™

Altered Dna Methylation Of Cyp2e1 Gene In Schizophrenia Patients With Tardive Dyskinesia, Ping Zhang, Yanli Li, Kesheng Wang, Junchao Huang, Brenda Bin Su, Chun Xu, Zhiren Wang, Shuping Tan, Fude Yang, Yunlong Tan

Health & Biomedical Sciences Faculty Publications and Presentations

Background

About 20–30% of patients with schizophrenia develop tardive dyskinesia (TD). Oxidative stress is one potential causes of TD. CYP2E1 is considered as an oxidative stress-related gene, however, no study has been reported on the DNA methylation levels of the CYP2E1 in schizophrenia or TD.

Methods

A total of 35 schizophrenia patients with TD, 35 schizophrenia patients without TD (NTD), and 35 health controls (HCs) were collected in Beijing, China. DNA was extracted from peripheral blood samples. The promoter methylation levels of CYP2E1 were detected using pyrosequencing. The generalized linear model (GLM) was used to examine the methylation levels of …

Improving The Management Of Tardive Dyskinesia On An Inpatient Mental Health Unit, Jennifer Krebsbach

Nursing Posters

Implement a practice change on the adult mental health unit to improve the accuracy and increase the rate of completion of the abnormal involuntary movement scale (AIMS) for tardive dyskinesia (TD).

Tardive Dyskinesia In Older Persons Taking Antipsychotics, Leslie Citrome, Stuart H Isaacson, Danielle Larson, Daniel Kremens

Department of Neurology Faculty Papers

Tardive dyskinesia (TD) is a hyperkinetic movement disorder caused by the use of dopamine receptor-blocking agents (DRBAs), a category of medications that includes first-and second-generation antipsychotics (APs) and agents such as metoclopramide that are used for the treatment of nausea and gastrointestinal dysmotility. While TD can affect people of all ages, older age is associated with increased risk of TD and also with the emergence of TD occurring after shorter treatment durations and lower dosages of DRBAs. TD is characterized by involuntary movements that include the face, limbs, and trunk, and is associated with increased comorbidities, social stigmatization, and impaired …

Valbenazine Has A Small But Meaningful Benefit For Tardive Dyskinesia, Joseph Friedli, Ryan Quick, Reem Sobh, Samantha Cowing

Clinical Research in Practice: The Journal of Team Hippocrates

A critical appraisal and clinical application of

Hauser RA, Factor SA, Marder SR, et al. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry. 2017;174(5):476-484. https://doi.org/10.1176/appi.ajp.2017.16091037

and

Factor SA, Remington G, Comella CL, et al. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. J Clin Psychiatry. 2017;78(9):1344-1350. https://doi.org/10.4088/JCP.17m11777

exploring the efficacy of a newer therapy for tardive dyskinesia, and describing recommendations for a patient with acute medical problems and longstanding tardive dyskinesia.

Pyrosequencing Analysis Of Irs1 Methylation Levels In Schizophrenia With Tardive Dyskinesia, Yanli Li, Kesheng Wang, Ping Zhang, Junchao Huang, Ying Liu, Zhiren Wang, Yongke Lu, Shuping Tan, Fude Yang, Yunlong Tan

Pharmacology, Physiology and Toxicology

Tardive dyskinesia (TD) is a serious side effect of certain antipsychotic medications that are used to treat schizophrenia (SCZ) and other mental illnesses. The methylation status of the insulin receptor substrate 1 (IRS1) gene is reportedly associated with SCZ; however, no study, to the best of the authors' knowledge, has focused on the quantitative DNA methylation levels of the IRS1 gene using pyrosequencing in SCZ with or without TD. The present study aimed to quantify DNA methylation levels of 4 CpG sites in the IRS1 gene using a Chinese sample including SCZ patients with TD and without TD (NTD) and …

Abnormal Involuntary Movement Scale In Tardive Dyskinesia: Minimal Clinically Important Difference, M. Stacy, M. Sajatovic, J. M. Kane, A. J. Cutler, G. S. Liang, C. F. O'Brien, C. U. Correll

Journal Articles

No abstract provided.

Treatment Of Tardive Dyskinesia With Vmat-2 Inhibitors: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials, M. Solmi, G. Pigato, J. M. Kane, C. U. Correll

Journal Articles

No abstract provided.

What Is The Risk-Benefit Ratio Of Long-Term Antipsychotic Treatment In People With Schizophrenia?, C. U. Correll, J. M. Rubio, J. M. Kane

Journal Articles

No abstract provided.

Tardive Dyskinesia Risk With First- And Second-Generation Antipsychotics In Comparative Randomized Controlled Trials: A Meta-Analysis, M. Carbon, J. M. Kane, S. Leucht, C. U. Correll

Journal Articles

No abstract provided.

Altered Il-2, Il-6 And Il-8 Serum Levels In Schizophrenia Patients With Tardive Dyskinesia, Hui-Mei An, Yun Long Tan, Jing Shi, Zhi-Ren Wang, Jair C. Soars, Jing Qin Wu, Fu-De Yang, Xu-Feng Huang, Xiang Yang Zhang

Xu-Feng Huang

Immune deregulation has been postulated to be one of the mechanisms underlying the pathogenesis of tardive dyskinesia (TD). We hypothesized that interleukins would have a link with TD in schizophrenia patients. In this study, the serum IL-2, IL-6 and IL-8 levels were examined by enzyme-linked immunosorbent assay (ELISA) in schizophrenia patients with TD (n = 48) and without TD (n = 45), and healthy controls (n = 44). The psychopathological symptoms of schizophrenia were assessed by the Positive and Negative Syndrome Scale (PANSS). The severity of TD was evaluated using Abnormal Involuntary Movement Scale (AIMS). The results showed that serum …

A Comparison Of A Mentally Ill Individual's Right To Refuse Medication Under The United States And The New York State Constitutions, William M. Brooks

Touro Law Review

No abstract provided.

Tardive Dyskinesia: A Prevalence Study In An Outpatient Population, Virginia J. Ravizza

Community & Environmental Health Theses & Dissertations

The purpose of this prevalence study was to assess the occurrence of tardive dyskinesia among a chronically mentally ill sample of a suburban mental health clinic. The participants in this study were selected from clients of a suburban mental health clinic who agreed to participate in this prevalence study. There were 45 participants--17 males and 28 females.

The Abnormal Involuntary Movement Scale (AIMS) was selected as the instrument to measure the abnormal involuntary movements exhibited by the participants of the study on the day of testing. The testing occurred during a specific time period, June 8, 1987 to July 2, …